Batterham, M
Those relying solely on medication lost 75% fat and 25% muscle
Diabetologia 54 , 2531 (2011)
The standard cagrilintide monotherapy titration follows this schedule: 0.25 mg weekly for weeks 1-4, then 0.5 mg for weeks 5-8, then 1.0 mg for weeks 9-12, then 1.7 mg for weeks 13-16, and finally 2.4 mg for week 17 onward as the maintenance dose
A 2017 systematic review and meta analysis of almost 90 studies on fat loss observed: Despite most people carrying more subcutaneous fat, weight loss interventions, including prescription drugs, produce a greater percentage of visceral fat loss
Peptide YY and other satiety peptides demonstrate clear physiological roles, with early failures attributable to rapid exposure and intolerance rather than to a lack of efficacy, again favoring re-evaluation